ll antipsychotics are created equal since they all block dopamine receptors. However, some antipsychotics are more equal than others and become atypical if they leave the dopamine receptor quickly after blocking it. 1 We posed the question, What makes an antipsychotic atypical? in an earlier BRAINSTORMS 2, 3 in which the atypical properties were then defined clinically as reduced side effects and pharmacologically as serotonin-2A (5-HT 2A ) antagonism associated with dopamine-2 (D 2 ) antagonism. Now, it appears that the length of time these drugs bind to D 2 receptors may be relevant as well. 1 Here we discuss this new hypothesis, and next month we will illustrate it. [4] [5] [6] Why would fast dissociation from D 2 receptors make an antipsychotic atypical?
Another idea about why antipsychotics are atypical is that they stay around long enough to cause an antipsychotic action but not long enough to cause side effects. 1 Theoretically, it takes only a quick blockade of the D 2 receptor to cause an antipsychotic ac-
What makes an antipsychotic conventional?
Conventional antipsychotics, also known as classical neuroleptics, all block D 2 receptors throughout the brain. 4 This action theoretically reduces dopamine hyperactivity in mesolimbic dopamine pathways thought to mediate psychosis. It also reduces dopamine activity in nigrostriatal dopamine pathways and causes extrapyramidal side effects and tardive dyskinesia.
Why would 5-HT 2A antagonism make an antipsychotic atypical?
Atypical antipsychotics have antipsychotic actions with much reduced or absent extrapyramidal side effects and tardive dyskinesia. 4 Theoretically, this effect could be the result of blockade of 5-HT 2A receptors in addition to D 2 receptors. Also, rapid dissociation from the D 2 receptor in vitro is a good predictor of low extrapyramidal side effect potential. 8 Since rapid dissociation occurs more readily when the drug has low potency, low-potency agents (i.e., those requiring higher milligram doses such as clozapine and quetiapine) have faster dissociation from the D 2 receptor than high-potency agents (i.e., those requiring lower milligram doses such as risperidone), with intermediatepotency agents, such as olanzapine, in the middle. This process roughly correlates with the abilities of these drugs to cause motor side effects within the group of atypical antipsychotics and also sets all of them apart from the conventional antipsychotics.
One of the consequences of fast dissociation is that the drug is gone from the receptor until the next dose. This means that natural dopamine can bathe the receptor for a while before the next pulse of drug. Perhaps a bit of real dopamine in the nigrostriatal dopamine system is all that is needed to prevent motor side effects. If natural dopamine is available in the nigrostriatal pathway while there is yet insufficient dopamine in the mesolimbic dopamine system to reactivate psychosis between doses, the drug has atypical antipsychotic clinical properties.
Summary
Either 
